OPKO Health, Inc. Operating Lease Cost
OPKO Health, Inc. (OPK) reported Operating Lease Cost of $8.50 million for the 6-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-28
- OPKO Health, Inc. operating lease, cost for the quarter ending 2026-06-30 was $4.30M, a 7.50% increase year-over-year.
- OPKO Health, Inc. operating lease, cost for the quarter ending 2026-03-31 was $4.20M, a 53.33% decline year-over-year.
- OPKO Health, Inc. operating lease, cost for the quarter ending 2025-12-31 was $4.80M, a 68.83% decline year-over-year.
- OPKO Health, Inc. operating lease, cost for the quarter ending 2025-09-30 was $3.50M, a 41.67% decline year-over-year.
- OPKO Health, Inc. operating lease, cost for fiscal 2025 was $21.30M, a 30.39% decline from fiscal 2024.
- OPKO Health, Inc. operating lease, cost for fiscal 2024 was $30.60M, a 84.34% increase from fiscal 2023.
- OPKO Health, Inc. operating lease, cost for fiscal 2023 was $16.60M, a 0.00% change from fiscal 2022.
- OPKO Health, Inc. operating lease, cost for fiscal 2022 was $16.60M, a 7.78% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4.30M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | $8.50M 10-Q/A · filed 2026-08-28 | $13.30M derived: sum of 3 quarters · filed 2026-08-28 | $16.80M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2026-03-31 | $4.20M 10-Q/A · filed 2026-08-28 | $9.00M derived: sum of 2 quarters · filed 2026-08-28 | $12.50M derived: sum of 3 quarters · filed 2026-08-28 | $16.50M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2025-12-31 | $4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.30M derived: sum of 2 quarters · filed 2026-02-26 | $12.30M derived: sum of 3 quarters · filed 2026-08-28 | $21.30M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $3.50M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2025-10-29 | $7.50M derived: sum of 2 quarters · filed 2026-08-28 | $16.50M 10-Q · filed 2025-10-29 | $31.90M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2025-06-30 | $4.00M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | $13.00M 10-Q/A · filed 2026-08-28 | $28.40M derived: sum of 3 quarters · filed 2026-08-28 | $34.40M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2025-03-31 | $9.00M 10-Q/A · filed 2026-08-28 | $24.40M derived: sum of 2 quarters · filed 2026-08-28 | $30.40M derived: sum of 3 quarters · filed 2026-08-28 | $35.20M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2024-12-31 | $15.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.40M derived: sum of 2 quarters · filed 2026-02-26 | $26.20M derived: sum of 3 quarters · filed 2026-02-26 | $30.60M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $10.80M derived: sum of 2 quarters · filed 2025-10-29 | $15.20M 10-Q · filed 2025-10-29 | $19.80M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $4.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $9.20M 10-Q · filed 2025-07-31 | $13.80M derived: sum of 3 quarters · filed 2026-02-26 | $17.60M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $4.40M 10-Q · filed 2025-05-01 | $9.00M derived: sum of 2 quarters · filed 2026-02-26 | $12.80M derived: sum of 3 quarters · filed 2026-02-26 | $16.90M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.40M derived: sum of 2 quarters · filed 2026-02-26 | $12.50M derived: sum of 3 quarters · filed 2026-02-26 | $16.60M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $7.90M derived: sum of 2 quarters · filed 2024-11-07 | $12.00M 10-Q · filed 2024-11-07 | $16.20M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-06-30 | $4.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $8.20M 10-Q · filed 2024-08-07 | $8.30M 10-Q · filed 2023-08-03 | $12.40M derived: sum of 3 quarters · filed 2025-03-03 | $16.40M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $4.10M 10-Q · filed 2024-05-07 | $8.30M derived: sum of 2 quarters · filed 2025-03-03 | $12.30M derived: sum of 3 quarters · filed 2025-03-03 | $16.10M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $8.20M derived: sum of 2 quarters · filed 2025-03-03 | $12.00M derived: sum of 3 quarters · filed 2025-03-03 | $16.60M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $7.80M derived: sum of 2 quarters · filed 2023-11-06 | $12.40M 10-Q · filed 2023-11-06 | $12.50M 10-Q · filed 2022-11-08 | $17.00M derived: sum of 4 quarters · filed 2024-03-01 | |
| 2022-06-30 | $3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $8.40M 10-Q · filed 2023-08-03 | $13.00M derived: sum of 3 quarters · filed 2024-03-01 | $17.30M derived: sum of 4 quarters · filed 2024-03-01 | ||
| 2022-03-31 | $4.60M 10-Q · filed 2023-05-03 | $9.20M derived: sum of 2 quarters · filed 2024-03-01 | $13.50M derived: sum of 3 quarters · filed 2024-03-01 | $18.10M derived: sum of 4 quarters · filed 2024-03-01 | ||
| 2021-12-31 | $4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $8.90M derived: sum of 2 quarters · filed 2024-03-01 | $13.50M derived: sum of 3 quarters · filed 2024-03-01 | $18.00M 10-K · filed 2024-03-01 | ||
| 2021-09-30 | $4.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $8.90M derived: sum of 2 quarters · filed 2022-11-08 | $13.40M 10-Q · filed 2022-11-08 | $17.50M derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-06-30 | $4.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $9.10M 10-Q · filed 2022-08-04 | $13.20M derived: sum of 3 quarters · filed 2023-02-27 | $17.20M derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-03-31 | $4.50M 10-Q · filed 2022-05-09 | $8.60M derived: sum of 2 quarters · filed 2023-02-27 | $12.60M derived: sum of 3 quarters · filed 2023-02-27 | $17.70M derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2020-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $8.10M derived: sum of 2 quarters · filed 2023-02-27 | $13.20M derived: sum of 3 quarters · filed 2023-02-27 | $17.80M 10-K · filed 2023-02-27 | ||
| 2020-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $9.10M derived: sum of 2 quarters · filed 2021-10-28 | $13.70M 10-Q · filed 2021-10-28 | $18.60M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $5.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $9.70M 10-Q · filed 2021-07-29 | $14.60M derived: sum of 3 quarters · filed 2022-03-01 | $20.10M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $4.60M 10-Q · filed 2021-04-28 | $9.50M derived: sum of 2 quarters · filed 2022-03-01 | $15.00M derived: sum of 3 quarters · filed 2022-03-01 | $19.10M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $10.40M derived: sum of 2 quarters · filed 2022-03-01 | $14.50M derived: sum of 3 quarters · filed 2022-03-01 | $20.20M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $5.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $9.60M derived: sum of 2 quarters · filed 2020-10-29 | $15.30M 10-Q · filed 2020-10-29 | |||
| 2019-06-30 | $4.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $9.80M 10-Q · filed 2020-07-31 | ||||
| 2019-03-31 | $5.70M 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |